Business
Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan
Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan PRESS RELEASE REGULATED INFORMATION / INSIDE INFORMATION23 December 2025, 6:30 pm CET / 12:30 pm ET Letter of intent to amend the loan from funds managed by Kreos, including an extension of the interest only period and deferral of amortization paymentsAdditional runway supports ongoing alfapump commercial rollout in the U.S. Ghent, Belgium – 23 December 2025
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I6pT.8uzi87Vh1qGIu6GAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Sequana Medical announces execution of letter of intent to amend terms of the Kreos Loan","length":138,"tagName":"p"},{"type":"text","content":"PRESS RELEASE REGULATED INFORMATION / INSIDE INFORMATION23 December 2025, 6:30 pm CET / 12:30 pm ET","length":106,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Letter of intent to amend the loan from funds managed by Kreos, including an extension of the interest only period and deferral of amortization payments","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional runway supports ongoing alfapump commercial rollout in the U.S.","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":226,"olType":false},{"type":"text","content":"Ghent, Belgium – 23 December 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced that it entered into a non-binding letter of intent with Kreos Capital VII (UK) Limited (together with its affiliates, "Kreos")1 to agree to a number of amendments to the terms of its loan (the "Kreos Loan"), including notably that the interest only period will be extended, and amortisation repayments will be postponed until 1 May 2026, and that the first two monthly repayments of principal and interest following the new amortisation resumption date (i.e., the 1 May and 1 June payments) shall equal half of each of the monthly repayments of principal and interest for the remaining three (3) months of amortisation to the final repayment date of 1 September 2026. The amendments are subject to the entry into a final binding agreement with Kreos. As a result of converting a porti...